Skip to content
value.today

Chroma Medicine, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2020
Total raised
$135 M
1 round on record
Latest round
$135 M
Feb 2023
First round on record
Feb 2023
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Chroma Medicine, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2023$135 MNo. 1$50 to $250 million

Chroma Medicine, Inc.: Raise no. 1, Feb 2023

Investors in this round

21 investors had bought by the notice of Sep 1, 2023: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$135 M of $135 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brett Kaplan · Executive Officer
  • Catherine Stehman-Breen · Executive Officer, Director
  • Vic Myer · Executive Officer
  • Bihua Chen · Director
  • George Golumbeski · Director
  • Jeff Marrazzo · Director
  • Kevin Bitterman · Director
  • Michael Kelly · Director
  • Paola Pozzi · Director
  • Thomas Cahill · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brett Kaplan, Chief financial officer. Newest notice filed Sep 1, 2023 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Chroma Medicine, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2023).

    SEC Form D · Sep 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2023

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Chroma Medicine, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Chroma Medicine, Inc.
NameRoleNamed in
Brett KaplanExecutive officerSep 2023
Catherine Stehman-BreenExecutive officerSep 2023
Vic MyerExecutive officerSep 2023
Bihua ChenDirectorSep 2023
Catherine Stehman-BreenDirectorSep 2023
George GolumbeskiDirectorSep 2023
Jeff MarrazzoDirectorSep 2023
Kevin BittermanDirectorSep 2023
Michael KellyDirectorSep 2023
Paola PozziDirectorSep 2023
Thomas CahillDirectorSep 2023